BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 179 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,731,336 | +6.4% | 385,782 | +5.8% | 0.00% | 0.0% |
Q2 2023 | $2,566,538 | +77.5% | 364,565 | +110.3% | 0.00% | 0.0% |
Q1 2023 | $1,446,031 | -23.6% | 173,385 | +5.2% | 0.00% | 0.0% |
Q4 2022 | $1,892,685 | -8.1% | 164,868 | +0.9% | 0.00% | 0.0% |
Q3 2022 | $2,060,000 | +4.1% | 163,453 | -12.6% | 0.00% | 0.0% |
Q2 2022 | $1,978,000 | -33.7% | 186,937 | +1.9% | 0.00% | 0.0% |
Q1 2022 | $2,983,000 | +36.6% | 183,447 | +16.4% | 0.00% | 0.0% |
Q4 2021 | $2,183,000 | -3.5% | 157,562 | +0.0% | 0.00% | 0.0% |
Q3 2021 | $2,263,000 | +210.9% | 157,547 | +242.0% | 0.00% | – |
Q2 2021 | $728,000 | +44.4% | 46,063 | -7.1% | 0.00% | – |
Q1 2021 | $504,000 | +31.2% | 49,572 | -3.9% | 0.00% | – |
Q4 2020 | $384,000 | +204.8% | 51,583 | +39.9% | 0.00% | – |
Q3 2020 | $126,000 | -35.4% | 36,869 | -9.9% | 0.00% | – |
Q2 2020 | $195,000 | +134.9% | 40,921 | -1.0% | 0.00% | – |
Q1 2020 | $83,000 | -38.1% | 41,327 | +6.7% | 0.00% | – |
Q4 2019 | $134,000 | +63.4% | 38,725 | +35.5% | 0.00% | – |
Q3 2019 | $82,000 | 0.0% | 28,582 | +32.8% | 0.00% | – |
Q2 2019 | $82,000 | -47.8% | 21,525 | +11.4% | 0.00% | – |
Q1 2019 | $157,000 | +0.6% | 19,315 | 0.0% | 0.00% | – |
Q4 2018 | $156,000 | +20.9% | 19,315 | +14.5% | 0.00% | – |
Q3 2018 | $129,000 | +43.3% | 16,862 | +7.2% | 0.00% | – |
Q2 2018 | $90,000 | +5.9% | 15,730 | -11.9% | 0.00% | – |
Q1 2018 | $85,000 | -29.2% | 17,849 | -26.4% | 0.00% | – |
Q4 2017 | $120,000 | +6.2% | 24,265 | +12.6% | 0.00% | – |
Q3 2017 | $113,000 | +10.8% | 21,553 | +17.5% | 0.00% | – |
Q2 2017 | $102,000 | -30.1% | 18,346 | +4.9% | 0.00% | – |
Q1 2017 | $146,000 | +29.2% | 17,486 | -1.4% | 0.00% | – |
Q4 2016 | $113,000 | +135.4% | 17,727 | +62.5% | 0.00% | – |
Q3 2016 | $48,000 | +54.8% | 10,906 | 0.0% | 0.00% | – |
Q2 2016 | $31,000 | +3.3% | 10,906 | 0.0% | 0.00% | – |
Q1 2016 | $30,000 | -73.2% | 10,906 | 0.0% | 0.00% | – |
Q4 2015 | $112,000 | -8.9% | 10,906 | 0.0% | 0.00% | – |
Q3 2015 | $123,000 | -27.6% | 10,906 | 0.0% | 0.00% | – |
Q2 2015 | $170,000 | +75.3% | 10,906 | 0.0% | 0.00% | – |
Q1 2015 | $97,000 | -27.1% | 10,906 | 0.0% | 0.00% | – |
Q4 2014 | $133,000 | +20.9% | 10,906 | 0.0% | 0.00% | – |
Q3 2014 | $110,000 | – | 10,906 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |